Deputy Physician in Chief- Translational Research Memorial Sloan Kettering New York, New York, United States
Session Description: Acute myeloid leukemia (AML) is an aggressive neoplasm with substantial clinical heterogeneity, owing in part to the underlying genetic heterogeneity. Over the past decade, data from bulk sequencing studies have been used to create stepwise mutational models of AML tumorigenesis; however, bulk sequencing studies are unable to accurately elucidate clonal architecture or evolution. This session will cover recent updates on how single-cell sequencing allows for single cell resolution of clonal architecture, and how specific mutations and mutational combinations can affect disease initiation, progression, and response to therapy.
If this session topic is of interest to you, please consider looking at the following course on AMP EDucation (AMPED™ Online)
Title: Mutational Signatures in cancer: Recent Findings, Laboratory Considerations, and Clinical Implications Click here to learn more.
Learning Objectives:
Upon completion, participants will be able to describe single cell sequencing technology and uses.
Upon completion, participants will be able to critique common misconceptions regarding use of variant allelic fractions to infer clonal architecture.
Upon completion, participants will be able to explain mutational models of AML tumorigenesis, including which mutations and combinations are responsible for tumor initiation and progression.
